A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
NCT06563505 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2026-01-21
Summary
To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.
Conditions
Interventions
- DRUG
-
Given by IV
- DRUG
-
Mosunetuzumab
Given by IV
Sponsors & Collaborators
-
M.D. Anderson Cancer Center
lead OTHER
Principal Investigators
-
Dai Chihara, MD,PHD · M.D. Anderson Cancer Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-12-11
- Primary Completion
- 2026-12-31
- Completion
- 2028-12-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT02500407 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT06859008 ·Status: RECRUITING ·Phase: PHASE1
-
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
NCT06883526 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
NCT01891981 ·Status: TERMINATED ·Phase: PHASE1
-
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
NCT00005950 ·Status: TERMINATED ·Phase: PHASE2
-
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
NCT06536049 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
NCT07031700 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell
NCT00656084 ·Status: COMPLETED ·Phase: PHASE2
-
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05633615 ·Status: RECRUITING ·Phase: PHASE2
-
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
NCT05207670 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996 ·Status: RECRUITING ·Phase: PHASE3
-
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05315713 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
NCT00005601 ·Status: COMPLETED ·Phase: PHASE2
-
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06015880 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease
NCT00284804 ·Status: COMPLETED ·Phase: PHASE2
-
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
NCT02470091 ·Status: COMPLETED ·Phase: PHASE2
-
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
NCT01055314 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
NCT02568553 ·Status: COMPLETED ·Phase: PHASE1
-
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
NCT05260957 ·Status: RECRUITING ·Phase: PHASE2
-
MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma
NCT00059995 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
NCT06029270 ·Status: RECRUITING ·Phase: PHASE2
-
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
NCT07283679 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
NCT04594187 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
NCT06930651 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02950220 ·Status: COMPLETED ·Phase: PHASE1